• Company
• Sanofi’s Hexaxim is included in NIP from this year
• by Whang, byung-woo Jan 10, 2025 05:52am

• Company
• Hexaxim may be administered in general hospitals in Korea
• by Eo, Yun-Ho Jan 10, 2025 05:52am

• Company
• Lilly Korea releases Ebglyss for atopic dermatitis in Korea
• by Whang, byung-woo Jan 10, 2025 05:52am

• Company
• Leclaza’s new trial data shows improved OS
• by Son, Hyung Min Jan 9, 2025 05:57am

• Company
• Vabysmo approved for retinal vein occlusion macular edema
• by Whang, byung-woo Jan 9, 2025 05:56am

• Company
• Krazati receives orphan drug designation in Korea
• by Eo, Yun-Ho Jan 9, 2025 05:56am

• Company
• Wegovy vs Mounjaro in KOR…who's the winner?
• by Moon, sung-ho Jan 9, 2025 05:56am

• Company
• Sales of Flu drug Tamiflu did not fare so well last year
• by Nho, Byung Chul Jan 8, 2025 05:53am

• Company
• J.P. Morgan selects ADC and obesity as big deal keywords
• by Moon, sung-ho Jan 8, 2025 05:53am

• Company
• Expansion of NIP needed for 20-valent pneumococcal vaccine
• by Whang, byung-woo Jan 8, 2025 05:53am